Ocahep (Obeticholic acid) acid is a semi-synthetic bile acid analogue which has the chemical structure 6α-ethyl-chenodeoxycholic acid. It is used as a drug to treat primary biliary cholangitis, and is undergoing development for several other liver diseases and related disorders
Obeticholic acid a farnesoid-X receptor (FXR) agonist, an USFDA (2016) approved molecule indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
Obeticholic acid 5mg/10mg
MODE OF ACTION:
Obeticholic acid is a potent agonist of the farnesoid X receptor, which serves to regulate the hepatic metabolism of bile and cholesterol. This drug acts by binding to the farnesoid X receptor, found in the nucleus of liver and intestinal cells, which in turn increases liver bile flow, suppressing its production and decreasing hepatocytes exposure to excess levels of bile with cholestasis. Cholestasis is a process that normally causes inflammation and cirrhosis of the liver. Farnesoid X receptor activation has the potential to not only regulate bile acid homeostasis but also have positive effects on inflammation and fibrotic pathways.
- Primary Biliary Cholangitis (PBC)
- Nonalcoholic Steatohepatitis (NASH)
Dosing depends on the severity of disease
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.